240 related articles for article (PubMed ID: 24690227)
1. Safety of the first dose of fingolimod for multiple sclerosis: results of an open-label clinical trial.
Laroni A; Brogi D; Morra VB; Guidi L; Pozzilli C; Comi G; Lugaresi A; Turrini R; Raimondi D; Uccelli A; Mancardi GL;
BMC Neurol; 2014 Apr; 14():65. PubMed ID: 24690227
[TBL] [Abstract][Full Text] [Related]
2. [Clinical significance of the cardiovascular effects of fingolimod treatment in multiple sclerosis].
Széplaki G; Merkely B
Ideggyogy Sz; 2012 Nov; 65(11-12):369-76. PubMed ID: 23289171
[TBL] [Abstract][Full Text] [Related]
3. Assessment of cardiac safety during fingolimod treatment initiation in a real-world relapsing multiple sclerosis population: a phase 3b, open-label study.
Gold R; Comi G; Palace J; Siever A; Gottschalk R; Bijarnia M; von Rosenstiel P; Tomic D; Kappos L;
J Neurol; 2014 Feb; 261(2):267-76. PubMed ID: 24221641
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial.
Calabresi PA; Radue EW; Goodin D; Jeffery D; Rammohan KW; Reder AT; Vollmer T; Agius MA; Kappos L; Stites T; Li B; Cappiello L; von Rosenstiel P; Lublin FD
Lancet Neurol; 2014 Jun; 13(6):545-56. PubMed ID: 24685276
[TBL] [Abstract][Full Text] [Related]
5. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.
Kappos L; Radue EW; O'Connor P; Polman C; Hohlfeld R; Calabresi P; Selmaj K; Agoropoulou C; Leyk M; Zhang-Auberson L; Burtin P;
N Engl J Med; 2010 Feb; 362(5):387-401. PubMed ID: 20089952
[TBL] [Abstract][Full Text] [Related]
6. The real-life experience with cardiovascular complications in the first dose of fingolimod for multiple sclerosis.
Fragoso YD; Arruda CC; Arruda WO; Brooks JB; Damasceno A; Damasceno CA; Finkelsztejn A; Finkelsztejn J; Gama PD; Giacomo MC; Gomes S; Goncalves MV; Matta AP; de Morais MM; Oliveira EM; Ribeiro Y; Sato HK; Tauil CB
Arq Neuropsiquiatr; 2014 Sep; 72(9):712-4. PubMed ID: 25252236
[TBL] [Abstract][Full Text] [Related]
7. Fingolimod-induced atrioventricular conduction defects in a young lady with multiple sclerosis--insights into possible drug mechanism.
Voon V; Saiva L; O'Kelly S; Keane D
Eur J Clin Pharmacol; 2014 Mar; 70(3):373-5. PubMed ID: 24309839
[No Abstract] [Full Text] [Related]
8. Delayed fingolimod-associated asystole.
Espinosa PS; Berger JR
Mult Scler; 2011 Nov; 17(11):1387-9. PubMed ID: 21652609
[TBL] [Abstract][Full Text] [Related]
9. Fingolimod: a review of its use in relapsing-remitting multiple sclerosis.
Sanford M
Drugs; 2014 Aug; 74(12):1411-33. PubMed ID: 25063048
[TBL] [Abstract][Full Text] [Related]
10. A randomized, controlled trial of fingolimod (FTY720) in Japanese patients with multiple sclerosis.
Saida T; Kikuchi S; Itoyama Y; Hao Q; Kurosawa T; Nagato K; Tang D; Zhang-Auberson L; Kira J
Mult Scler; 2012 Sep; 18(9):1269-77. PubMed ID: 22354739
[TBL] [Abstract][Full Text] [Related]
11. Trial watch: Phase III promise for oral multiple sclerosis therapy.
Nat Rev Drug Discov; 2009 Feb; 8(2):98. PubMed ID: 19180099
[No Abstract] [Full Text] [Related]
12. Overview and safety of fingolimod hydrochloride use in patients with multiple sclerosis.
Ward MD; Jones DE; Goldman MD
Expert Opin Drug Saf; 2014 Jul; 13(7):989-98. PubMed ID: 24935480
[TBL] [Abstract][Full Text] [Related]
13. Fingolimod-associated amenorrhea: a report of three cases.
Alroughani R
Mult Scler; 2014 Oct; 20(12):1662-4. PubMed ID: 24515730
[TBL] [Abstract][Full Text] [Related]
14. Long-term effects of fingolimod in multiple sclerosis: the randomized FREEDOMS extension trial.
Kappos L; O'Connor P; Radue EW; Polman C; Hohlfeld R; Selmaj K; Ritter S; Schlosshauer R; von Rosenstiel P; Zhang-Auberson L; Francis G
Neurology; 2015 Apr; 84(15):1582-91. PubMed ID: 25795646
[TBL] [Abstract][Full Text] [Related]
15. Oral fingolimod for the treatment of patients with relapsing forms of multiple sclerosis.
Singer B; Ross AP; Tobias K
Int J Clin Pract; 2011 Aug; 65(8):887-95. PubMed ID: 21679286
[TBL] [Abstract][Full Text] [Related]
16. Fingolimod therapy for multiple sclerosis.
Willis MA; Cohen JA
Semin Neurol; 2013 Feb; 33(1):37-44. PubMed ID: 23709211
[TBL] [Abstract][Full Text] [Related]
17. Fingolimod: a review of its use in the management of relapsing-remitting multiple sclerosis.
Scott LJ
CNS Drugs; 2011 Aug; 25(8):673-98. PubMed ID: 21790210
[TBL] [Abstract][Full Text] [Related]
18. Safety and Tolerability of Fingolimod in Latin American Patients with Relapsing-Remitting Multiple Sclerosis: The Open-Label FIRST LATAM Study.
Ordoñez-Boschetti L; Rey R; Cruz A; Sinha A; Reynolds T; Frider N; Alvarenga R
Adv Ther; 2015 Jul; 32(7):626-35. PubMed ID: 26170105
[TBL] [Abstract][Full Text] [Related]
19. [Fingolimod treatment in multiple sclerosis].
Tanaka M
Nihon Rinsho; 2014 Nov; 72(11):2010-4. PubMed ID: 25518386
[TBL] [Abstract][Full Text] [Related]
20. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.
Cohen JA; Barkhof F; Comi G; Hartung HP; Khatri BO; Montalban X; Pelletier J; Capra R; Gallo P; Izquierdo G; Tiel-Wilck K; de Vera A; Jin J; Stites T; Wu S; Aradhye S; Kappos L;
N Engl J Med; 2010 Feb; 362(5):402-15. PubMed ID: 20089954
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]